Marcin Skrzypski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4498148/publications.pdf

Version: 2024-02-01

567281 752698 22 1,086 15 20 citations h-index g-index papers 22 22 22 2103 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer. Oncogene, 2019, 38, 180-193.	5.9	35
2	A clonal expression biomarker associates with lung cancer mortality. Nature Medicine, 2019, 25, 1540-1548.	30.7	75
3	Cancer cachexia in thoracic malignancy: a narrative review. Current Opinion in Supportive and Palliative Care, 2019, 13, 316-322.	1.3	6
4	Can an Integrative SNP Approach Substitute Standard Identification in Comprehensive Case/Control Analyses?. Advances in Intelligent Systems and Computing, 2019, , 123-130.	0.6	0
5	Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer. Cancer Treatment Reviews, 2018, 66, 114-121.	7.7	28
6	MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma. Lung Cancer, 2018, 118, 111-118.	2.0	38
7	Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors. Wspolczesna Onkologia, 2017, 3, 254-258.	1.4	8
8	Keratin 7 expression in lymph node metastases but not in the primary tumour correlates with distant metastases and poor prognosis in colon carcinoma. Polish Journal of Pathology, 2016, 3, 228-234.	0.3	14
9	The Role of TRAF4 and B3GAT1 Gene Expression in the Food Hypersensitivity and Insect Venom Allergy in Mastocytosis. Archivum Immunologiae Et Therapiae Experimentalis, 2016, 64, 497-503.	2.3	9
10	Prognostic value of 5-microRNA based signature in T2-T3NO colon cancer. Clinical and Experimental Metastasis, 2016, 33, 765-773.	3. 3	52
11	Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations. BMC Genomics, 2015, 16, 752.	2.8	12
12	Main Histologic Types of Non–Small-Cell LungÂCancer Differ in Expression of Prognosis-related Genes. Clinical Lung Cancer, 2013, 14, 666-673.e2.	2.6	34
13	MicroRNA in lung cancer diagnostics and treatment. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011, 717, 25-31.	1.0	52
14	An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 284-290.	7.0	134
15	Quantitative reverse transcriptase real-time polymerase chain reaction (qRT-PCR) in translational oncology: Lung cancer perspective. Lung Cancer, 2008, 59, 147-154.	2.0	26
16	Analysis of Safety, Risk Factors and Pretreatment Methods during Rush Hymenoptera Venom Immunotherapy. International Archives of Allergy and Immunology, 2008, 147, 241-245.	2.1	27
17	Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung. Clinical Cancer Research, 2008, 14, 4794-4799.	7.0	99
18	A Multigene Assay Is Prognostic of Survival in Patients with Early-Stage Lung Adenocarcinoma. Clinical Cancer Research, 2008, 14, 5565-5570.	7.0	77

#	Article	IF	CITATIONS
19	Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncology, The, 2007, 8, 889-897.	10.7	140
20	BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer. PLoS ONE, 2007, 2, e1129.	2.5	200
21	9th Central European Lung Cancer Conference in Gdańsk. Lung Cancer, 2005, 49, 281-284.	2.0	O
22	P53and K-rasmutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma. Cancer, 2004, 100, 1951-1960.	4.1	20